Drug manufacturer Lilly indicated late last week that it reserves the right to seek additional compensation for its products from 340B covered entities if it learns later that it charged them less than what the company perceives the 340B statute allows.
Lilly staked out that position in a pair of otherwise routine notices to 340B covered entities about refunds for 340B overcharges posted on the U.S. Health Resources and Services Administration (HRSA) website.
Drug manufacturer Lilly indicated late last week that it reserves the right to seek additional compensation for its products from 340B covered entities if it learns later that it charged them less than the 340B statute allows.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
